Clinical Trial Update: Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of monoclonal antibody RAV12 with gemcitabine in metastatic pancreatic cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• RAV12

Snippet

Sponsor: MacroGenics | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-12-19